Bluebird’s star gene therapy patient still doing well after 15 months-plus; Takeda, Arix partner on biotech startups
→ Every biotech enjoys a good success story, and bluebird bio $BLUE got their writeup in the New England Journal of Medicine. Patient 1204 in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
